Delivering mRNA to the heart using EVs or LNPs: in their latest pre-print article, Nawaz Muhammad, Hadi Valadi at the University of Gothenburg and collaborators proposed that cardiac-specific extracellular vesicles could outperform non-cardiac EVs and lipid nanoparticles in delivering mRNA to the heart. In mice, intravenous administration of cardiac progenitor cell-derived EVs (CPC-EVs) demonstrated the highest efficiency in delivering modified mRNA encoding vascular endothelial growth factor A (VEGF-A) to the heart, with significantly reduced liver accumulation compared to non-cardiac EVs or LNPs https://lnkd.in/e_GhjmJm Immunofluorescence staining for CD31 and α-SMA, markers of microvascular density, revealed increased vessel density in mouse aortic rings following VEGF-A mRNA delivery via CPC-EVs. Their results highlight CPC-EVs as superior vectors for heart-specific mRNA delivery, promoting effective communication with cardiac cells, minimising off-target liver accumulation, and causing minimal transcriptomic alterations. Their findings highlight CPC-EVs as a promising platform for heart-targeted mRNA therapies. An article co-authored by Benyapa Tangruksa, Sepideh H.Hagvall, Franziska Kohl, Hernán González-King Garibotti, Yujia Jing, Zahra Payandeh (Ph.D.), Azadeh Reyahi, Karin Jennbacken, John Wiseman, Leif Hultin, Lennart Lindfors and Jane Synnergren #extracellularvesicles #LNPs #exosomes #mRNA #targeteddelivery #Vesiculab
Congrats on the paper Nawaz. Very exciting work.
Thank you all the co-authors for your contributions. It has been very rewarding working with this project.
Thank you for displayin a very excellent information or article.
Postdoctoral Scientist at UCLA
6moInteresting study! I wonder how liver accumulation would differ with other injection routes. Also, how do these EVs and LNPs compare in terms of scalability and stability for potential clinical applications?